Immix Biopharma
ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. We are developing an entirely new class of Tissue-Specific Therapeutics, or TSTx, which we believe will replace first-line therapies across a multitude of cancer indications.Content by Immix Biopharma
| 1 min read
A new kid on the block flips the script using a systems biology-inspired tissue-specific approach against metastatic cancer that normalizes the tumor microenvironment.
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Achieving bioanalytical precision and control
Advanced LIMS software helps researchers reliably manage complex bioanalytical workflows and data.
Maximizing NGS efficiency with magnetic beads
The latest magnetic bead technology cuts sample preparation time, producing consistent, reliable results.
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
